Journal of International Oncology››2015,Vol. 42››Issue (6): 439-441.doi:10.3760/cma.j.issn.1673-422X.2015.06.010
Previous ArticlesNext Articles
Lian Yifan, Wang Keming
Received:
2014-12-15Online:
2015-06-08Published:
2015-05-31Contact:
Wang Keming E-mail:wkmys@sohu.comLian Yifan, Wang Keming. Molecular mechanism of long non-coding RNAs in tumor drug resistance[J]. Journal of International Oncology, 2015, 42(6): 439-441.
[1] Milhem MM, Knutson T, Yang S, et al. Correlation of MTDH/AEG1 and HOTAIR expression with metastasis and response to treatment in sarcoma patients[J]. J Cancer Sci Ther, 2011, S5(4): 4. [2] Amit D, Hochberg A. Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2 P4 regulatory sequences[J]. Int J Clin Exp Med, 2012, 5(4): 296-305. [3] Pickard MR, MourtadaMaarabouni M, Williams GT. Long noncoding RNA GAS5 regulates apoptosis in prostate cancer cell lines[J]. Biochim Biophys Acta, 2013, 1832(10): 1613-1623. [4] Jiang M, Huang O, Xie Z, et al. A novel long noncoding RNAARA: adriamycin resistanceassociated[J]. Biochem Pharmacol, 2014, 87(2): 254-283. [5] Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities[J]. Nat Rev Cancer, 2009, 9(6): 400-414. [6] Grosset AA, Labrie M, Gagné D, et al. Cytosolic galectin7 impairs p53 functions and induces chemoresistance in breast cancer cells[J]. BMC Cancer, 2014, 14: 801. [7] Chen J, Lu H, Yan D, et al. PAK6 increase chemoresistance and is a prognostic marker for stage Ⅱ and Ⅲ colon cancer patients undergoing 5-FU based chemotherapy[J]. Oncotarget, 2015, 6(1): 355-367. [8] Li B, Gao Y, Rankin GO, et al. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53dependent pathway in cisplatinresistant ovarian cancer cells[J]. Cancer Lett, 2015, 356(2 Pt B): 418-433. [9] Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs[J]. Cell, 2007, 129(7): 1311-1323. [10] Liu Z, Sun M, Lu K, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21WAF1/CIP1 expression[J]. PLoS One, 2013, 8(10): e77293. [11] Zhang H, Cai K, Wang J, et al. MiR7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway[J]. Stem Cells, 2014, 32(11): 2858-2868. [12] Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion[J]. Proc Natl Acad Sci USA, 2000, 97(7): 3260-3265. [13] Mikhail S, Zeidan A. Stem cells in gastrointestinal cancers: the road less travelled[J]. World J Stem Cells, 2014, 6(5): 606-613. [14] Polakis P. Wnt signaling in cancer[J]. Cold Spring Harb Perspect Biol, 2012, 4(5): a008052. [15] Hu T, Li C, Cao Z, et al. Myristoylated Naked2 antagonizes Wntbetacatenin activity by degrading Dishevelled1 at the plasma membrane[J]. J Biol Chem, 2010, 285(18): 13561-13568. [16] Yang Y, Li H, Hou S, et al. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in nonsmallcell lung cancer cell[J]. PLoS One, 2013, 8(5): e65309. [17] Fan Y, Shen B, Tan M, et al. Long noncoding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling[J]. FEBS J, 2014, 281(7): 1750-1758. [18] Wang Y, Chen W, Yang C, et al. Long noncoding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer[J]. Int J Oncol, 2012, 41(1): 276-284. [19] 常冰梅, 姜蓬垒. PI3KAkt信号通路与肿瘤化疗耐药性[J]. 国际肿瘤学杂志, 2014, 41(5): 324-327. [20] Matouk IJ, Raveh E, Abulail R, et al. Oncofetal H19 RNA promotes tumor metastasis[J]. 2014, 1843(7): 1414-1426. [21] Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1associated drug resistance in human hepatocellular carcinoma cells[J]. Oncogene, 2007, 26(33): 4877-4881. [22] Wang Y, Zhang D, Wu K, et al. Long noncoding RNA MRUL promotes ABCB1 expression in multidrugresistant gastric cancer cell sublines[J]. Mol Cell Biol, 2014, 34(17): 3182-3193. [23] Takahashi K, Yan IK, Kogure T, et al. Extracellular vesiclemediated transfer of long noncoding RNA ROR modulates chemosensitivity in human hepatocellular cancer[J]. FEBS Open Bio, 2014, 4: 458-467. [24] Tsang WP, Wong TW, Cheung AH, et al. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR[J]. RNA, 2007, 13(6): 890-898. [25] Ding J, Li D, Gong M, et al. Expression and clinical significance of the long noncoding RNA PVT1 in human gastric cancer[J]. Onco Targets Ther, 2014, 7: 1625-1630. [26] You L, Chang D, Du HZ, et al. Genomewide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells[J]. Biochem Biophys Res Commun, 2011, 407(1): 1-6. [27] Tseng YY, Moriarity BS, Gong W, et al. PVT1 dependence in cancer with MYC copynumber increase[J]. Nature, 2014, 512(7512): 82-86. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[12] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[13] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[14] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[15] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||